135 related articles for article (PubMed ID: 27831487)
1. Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.
Ito Y; Kuraoka S; Endo S; Takahashi A; Onoue S; Yamada S
J Pharmacol Exp Ther; 2017 Jan; 360(1):69-74. PubMed ID: 27831487
[TBL] [Abstract][Full Text] [Related]
2. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
[TBL] [Abstract][Full Text] [Related]
3. Characterization of muscarinic receptor binding by the novel radioligand, [(3)H]imidafenacin, in the bladder and other tissues of rats.
Kuraoka S; Ito Y; Wakuda H; Shinozuka K; Onoue S; Yamada S
J Pharmacol Sci; 2016 Jul; 131(3):184-9. PubMed ID: 27430986
[TBL] [Abstract][Full Text] [Related]
4. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
5. Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland.
Yoshida A; Kuraoka S; Ito Y; Okura T; Deguchi Y; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
J Pharmacol Sci; 2014; 124(1):40-6. PubMed ID: 24389821
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
[TBL] [Abstract][Full Text] [Related]
7. Imidafenacin for the treatment of overactive bladder.
Leone Roberti Maggiore U; Scala C; Venturini PL; Ferrero S
Expert Opin Pharmacother; 2013 Jul; 14(10):1383-97. PubMed ID: 23641864
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.
Ohno T; Nakade S; Nakayama K; Kitagawa J; Miyabe H; Konomi T; Miyata Y
Drug Metab Pharmacokinet; 2008; 23(6):456-63. PubMed ID: 19122340
[TBL] [Abstract][Full Text] [Related]
9. Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder.
Shiho M; Akashita G; Nakatani E; Tanaka S; Yamada S; Okura T
Drug Metab Pharmacokinet; 2024 Jun; 56():100998. PubMed ID: 38583388
[TBL] [Abstract][Full Text] [Related]
10. Muscarinic receptors in the bladder: from basic research to therapeutics.
Hegde SS
Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task.
Kobayashi F; Yageta Y; Yamazaki T; Wakabayashi E; Inoue M; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(3):147-54. PubMed ID: 17469649
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder].
Uno T; Kobayashi F; Ogata A; Konomi T
Nihon Yakurigaku Zasshi; 2008 May; 131(5):379-87. PubMed ID: 18480570
[No Abstract] [Full Text] [Related]
13. In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats.
Yamazaki T; Muraki Y; Anraku T
Naunyn Schmiedebergs Arch Pharmacol; 2011 Sep; 384(3):319-29. PubMed ID: 21814879
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
Homma Y; Yamaguchi O
Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536
[TBL] [Abstract][Full Text] [Related]
15. Effects of vibegron, a novel β
Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
[TBL] [Abstract][Full Text] [Related]
16. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder.
Yoshida A; Fujino T; Maruyama S; Ito Y; Taki Y; Yamada S
J Pharmacol Sci; 2010; 112(2):142-50. PubMed ID: 20134113
[TBL] [Abstract][Full Text] [Related]
17. Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats.
Muraki Y
Naunyn Schmiedebergs Arch Pharmacol; 2015 Nov; 388(11):1171-8. PubMed ID: 26216447
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibitory effect of imidafenacin and 5-hydroxymethyl tolterodine on capsaicin sensitive C fibers of the primary bladder mechanosensitive afferent nerves in the rat.
Aizawa N; Ito H; Sugiyama R; Fujimura T; Suzuki M; Fukuhara H; Homma Y; Igawa Y
J Urol; 2015 Apr; 193(4):1423-32. PubMed ID: 25219701
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.
Abrams P; Andersson KE; Buccafusco JJ; Chapple C; de Groat WC; Fryer AD; Kay G; Laties A; Nathanson NM; Pasricha PJ; Wein AJ
Br J Pharmacol; 2006 Jul; 148(5):565-78. PubMed ID: 16751797
[TBL] [Abstract][Full Text] [Related]
20. Characterization of muscarinic and P2X receptors in the urothelium and detrusor muscle of the rat bladder.
Ogoda M; Ito Y; Fuchihata Y; Onoue S; Yamada S
J Pharmacol Sci; 2016 May; 131(1):58-63. PubMed ID: 27174863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
